PSI Advisors LLC Has $738,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

PSI Advisors LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 27,823 shares of the biopharmaceutical company’s stock after buying an additional 385 shares during the period. PSI Advisors LLC’s holdings in Pfizer were worth $738,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Thoroughbred Financial Services LLC raised its position in Pfizer by 102.9% during the second quarter. Thoroughbred Financial Services LLC now owns 32,173 shares of the biopharmaceutical company’s stock valued at $900,000 after purchasing an additional 16,313 shares in the last quarter. Redwood Wealth Management Group LLC raised its holdings in shares of Pfizer by 6.0% during the 2nd quarter. Redwood Wealth Management Group LLC now owns 24,865 shares of the biopharmaceutical company’s stock worth $696,000 after buying an additional 1,405 shares in the last quarter. Valley Forge Investment Consultants Inc. ADV bought a new stake in shares of Pfizer during the 2nd quarter worth $169,000. Bcwm LLC acquired a new stake in Pfizer in the second quarter valued at about $4,781,000. Finally, Bruce & Co. Inc. grew its position in Pfizer by 2.9% in the second quarter. Bruce & Co. Inc. now owns 276,400 shares of the biopharmaceutical company’s stock valued at $7,734,000 after acquiring an additional 7,900 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PFE. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Stock Performance

NYSE:PFE opened at $26.79 on Tuesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a 50 day simple moving average of $26.16 and a two-hundred day simple moving average of $28.04. The company has a market capitalization of $151.82 billion, a PE ratio of 36.20, a P/E/G ratio of 0.63 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.17) earnings per share. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.42%. Pfizer’s dividend payout ratio is presently 232.43%.

Insider Buying and Selling

In related news, Director Scott Gottlieb acquired 1,000 shares of the business’s stock in a transaction dated Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.06% of the stock is currently owned by insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.